HEALTHSTORY 566· JUNE 26, 2026

One Patient Has Been Granted Exclusive Access to Eli Lilly's Obesity Drug Retatrutide Through FDA Compassionate Use

The Food and Drug Administration and Eli Lilly have permitted a single individual to receive retatrutide — Lilly's highly anticipated obesity drug candidate — through the FDA's compassionate use program, according to a scoop by STAT News…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 565SpaceX Stock Slides 14%, on Pace for Third Straight Day of Losses as Post-IPO Rally Fades NEXT STORY 567 →Airwallex Raises $320 Million at $11 Billion Valuation to Build Financial Infrastructure for AI Agents

Keep reading

More from the desk.

14HEALTH

Seven months after launch, Aurora Therapeutics scraps its lead gene-editing program and cuts staff

Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid…

health2 MIN

29HEALTH

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

health2 MIN

40HEALTH

Trump administration shifts 340B drug program from upfront discounts to rebates, drawing hospital backlash

A federal law requires pharmaceutical manufacturers to sell discounted medicines to specific hospitals and clinics. That discount mechanism, the foundation of the 340B Drug Pricing Program, is now being reshaped. The Trump administration…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk